New Liver Drug Cuts Fat and Stiffness Fast Without Major Weight Loss
A Phase 2 trial shows zabopegdutide slashed liver fat in 73% of MASH patients within 12 weeks, even with minimal weight loss.
Summary
A new once-weekly injectable drug called zabopegdutide significantly reduced liver fat, stiffness, and scarring markers in people with fatty liver disease within just 12 weeks. In a randomized, placebo-controlled trial of 67 overweight or obese patients, nearly three-quarters achieved over 50% reduction in liver fat. Crucially, these liver benefits appeared even in patients who lost less than 5% of their body weight, suggesting the drug acts directly on the liver beyond just promoting weight loss. The drug targets two hormone receptors — GLP-1 and glucagon — and also improved blood sugar and cholesterol levels. These early results may predict lasting liver healing seen at 48 weeks in later biopsy data.
Detailed Summary
Fatty liver disease — specifically metabolic dysfunction-associated steatohepatitis (MASH) — is a growing global health crisis linked to obesity, type 2 diabetes, and accelerated aging of the liver. Without effective treatment, it can progress to cirrhosis, liver failure, or liver cancer. A new drug may change that trajectory.
D&D Pharmatech published 12-week data from a randomized, double-blind, placebo-controlled Phase 2 trial of zabopegdutide (DD01) in Lancet Gastroenterology & Hepatology. The trial enrolled 67 overweight or obese patients with MASH or its precursor condition. Results were striking: 75.8% of treated patients achieved at least a 30% reduction in liver fat, 72.7% exceeded 50% reduction, and nearly half achieved complete liver fat normalization below the 5% threshold. Liver stiffness and fibrosis biomarkers — including pro-C3 and the Enhanced Liver Fibrosis (ELF) score — also dropped significantly.
What sets zabopegdutide apart from existing GLP-1 drugs like semaglutide is evidence of a weight-independent hepatic effect. Among patients who lost less than 5% of body weight by week 12, liver fat still fell by 37.4% and liver stiffness by 19.2%. This suggests the drug's glucagon receptor activity may be directly targeting liver metabolism, not just reducing caloric intake. Patients who lost more weight saw larger liver improvements, indicating additive benefit.
The drug also improved glycemic control and lipid profiles — two major cardiovascular and metabolic risk factors — adding to its potential as a comprehensive metabolic therapy. These 12-week non-invasive markers correlated with histological improvements seen at 48-week biopsy, lending credibility to their use as early predictors of durable benefit.
Caveats remain: this is a Phase 2 trial with only 67 participants, and long-term safety, durability beyond 48 weeks, and comparison with approved therapies are still needed. Regulatory approval is far from certain, but the mechanism and early magnitude of effect are genuinely promising for liver longevity.
Key Findings
- 72.7% of treated patients achieved over 50% liver fat reduction within 12 weeks of treatment.
- Liver fat dropped 37.4% even in patients who lost less than 5% body weight, suggesting direct liver action.
- Liver stiffness fell 19.2% in low-weight-loss patients, indicating reduced fibrosis risk independent of weight loss.
- Fibrosis biomarkers pro-C3 and ELF score were significantly reduced at 12 weeks.
- Drug also improved blood sugar and cholesterol, offering broad metabolic benefit beyond the liver.
Methodology
This is a news report summarizing a published Phase 2 randomized, double-blind, placebo-controlled trial (NCT06410924) published in Lancet Gastroenterology & Hepatology, a high-credibility peer-reviewed journal. The sample size is small (67 patients) and findings are industry-sponsored by D&D Pharmatech, warranting independent replication.
Study Limitations
The trial enrolled only 67 patients, limiting statistical power and generalizability. Data are industry-sponsored, and independent replication in larger Phase 3 trials is needed before clinical adoption. Long-term safety beyond 48 weeks and head-to-head comparisons with approved MASH therapies have not yet been published.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: